Skip to main content
Toggle navigation
Search
Home
Poster Schedule
Home
Poster Schedule
All Days
Wed, Sep 17
Thu, Sep 18
Fri, Sep 19
Poster Schedule
Type here to filter the list
Friday, September 19, 2025
(PA-004) Real-world Bispecific Antibody Therapy for Multiple Myeloma: Insights from Dutch Nationwide Registry
(PA-007) Talquetamab Dosing Strategies in the United States: Real-world Insights from over 250 Patients
(PA-009) Acquired FCRL5 Mutation Leading to Cevostamab Resistance in Multiple Myeloma
(PA-010) Efficacy/safety of Cilta-cel ± Lenalidomide Maintenance in Patients with Multiple Myeloma Who Had Suboptimal Response to Frontline ASCT: Updated Follow-up from CARTITUDE-2 Cohort D
(PA-013) Synergistic Anti-tumor Effects of CAR T Cells and a Personalized Tumor Vaccine
(PA-015) Non-linear Impact of BMI on Anti-bcma CAR-T Outcomes: Overweight Paradox in Myeloma
(PA-016) Delayed Hematologic Recovery After BCMA CAR-T Is Associated with Progressive Loss of Endogenous T Cell Diversity After CAR-T Infusion
(PA-019) Factors Associated with Response, Neurotoxicity, and Survival in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell (CAR-T) Therapy
(PA-022) Real-World Long-Term Effectiveness and Safety Outcomes Among Patients Receiving Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
(PA-023) Outcomes of Teclistamab (Tec) Step-up Dosing in Outpatient/hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with Tec
(PA-027) Linvoseltamab (LINVO) Monotherapy in Patients (pts) with Newly Diagnosed (ND) Multiple Myeloma (MM): Initial Dose-escalation Results from the Window of Opportunity LINKER-MM4 Trial
(PA-029) Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma
(PA-030) Health Care Contact Days After Standard of Care (SOC) B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR T) for Relapsed/Refractory Multiple Myeloma (RRMM).
(PA-033) Reshaping Treatments: Insights from the BiTAL Study on Talquetamab in Relapsed Refractory Multiple Myeloma.
(PA-036) Effectiveness, Safety and Clinical Use of Teclistamab in Patients with Triple-class-exposed Multiple Myeloma. Data from the Danish ABC-study
(PA-037) Real World Accelerated Step-up Dosing of Teclistamab and Talquetamab in the Outpatient Setting Is Feasible and Associated with Low Incidence of Cytokine Release Syndrome
(PA-039) Differential Impact of BCMA (TNFRSF17) Extracellular Domain Mutations on in vitro Potency of Elranatamab versus Teclistamab
(PA-041) Enhanced Persistence and Antitumor Activity of IL-15–Armored Anti-BCMA CAR NK Cells in Myeloma Mouse Model.
(PA-042) Peak Absolute Lymphocyte Count as a Biomarker for CAR T-cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleuecel
(PA-043) Anti-BCMA-CAR-IL15 Natural Killer Cells Prevent Multiple Myeloma Growth in the Bone Marrow but Allow Later Emergence of Extramedullary Disease
(PA-044) Real-World Treatment Patterns Associated With Elranatamab Among Patients With Relapsed/Refractory Multiple Myeloma: The ALTITUDE-2 Study
(PA-047) Melphalan-Induced Enrichment of TP53-Mutant CHIP as a Risk Factor for Subsequent CAR-T Related Myeloid Neoplasms in Multiple Myeloma
(PA-049) Linvoseltamab in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM) in the LINKER-MM1 Study: Longer Follow-up and Subgroup Analyses
(PA-050) Comparative Efficacy of Linvoseltamab versus Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Triple-class Exposed Relapsed/refractory Multiple Myeloma: A Matching-adjusted Indirect Comparison
(PA-054) Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian Perspective
(PA-057) Outcomes of Outpatient Step-up Dosing (SUD) of Teclistamab and Talquetamab in Patients with Relapsed/refractory Multiple Myeloma (RRMM): Findings from a Large Network of Community Practices in the USA
(PA-058) Real-world Safety Outcomes and Healthcare Resource Utilization (HCRU) During Outpatient, Inpatient, and Hybrid Step-up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal): A Chart Review Study
(PA-061) Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
(PA-065) Real-World Outcomes of Equecabtagene Autoleucel, the First Fully Human BCMA-Targeted CAR-T Therapy, in 150 Patients with Multiple Myeloma (MM): A Multicenter Experience from China
(PA-066) Kinetic Characteristics of T Cells in CAR-T Therapy for Multiple Myeloma: A Real-World Analysis
(PA-067) Infections in Patients (PTS) with Multiple Myeloma (MM) Treated with BCMA-directed Car T Cell Therapies and Bispecific Antibodies: Analysis of the FDA Adverse Event Reporting System (FAERS)
(PA-070) An Evaluation of Overall Survival Between B-cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapies and Bispecific Antibodies for the Treatment of Relapsed/refractory Multiple Myeloma
(PA-072) Optimizing CAR-T Therapy in Multiple Myeloma: Outpatient Reinfusion of Cesnicabtagene Autoleucel (ARI0002h)
(PA-073) Linvoseltamab (LINVO) in Frail Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the LINKER-MM1 Study
(PA-077) Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
(PA-081) Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma — A Retrospective Evaluation
(PA-085) TRAIL-CD28 Armoring Enhances anti-BCMA CAR-T Cell Function and Overcomes Resistance in Multiple Myeloma
(PA-086) Real-world Healthcare Resource Utilization (HCRU) Following Outpatient (OP) or Inpatient (IP) Administration of Ciltacabtagene Autoleucel (Cilta-cel)
(PA-089) Debulking Chemotherapy Abrogates the Risk of Non-Response in Multiple Myeloma Patients with High Tumor Burden Receiving Teclistamab
(PA-092) Clinicopathological Analysis of Parkinsonism-like Neurotoxicity after BCMA-Directed CAR-T Therapy: An Autopsy Case With Idecabtagene-Vicleucel
(PA-094) Early Mortality Associated with Real-World Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
(PA-096) Abnormal Serum Immunofixation Patterns (ASIP) Are a Common Event Following BCMA CAR-T in Relapsed Refractory Multiple Myeloma and Are Often Preceded by Immunological Events
(PA-099) High ALC Peak Post Cilta-Cel Infusion Predicts Risk for Delayed Neurological Toxicities
(PA-102) Quality-adjusted Survival Analysis of Cilta-cel vs Standard of Care in Lenalidomide-refractory Multiple Myeloma Patients Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population
(PA-105) CART–ASCT–CART2 Sandwich Regimen as Frontline Therapy: A Phase II Trial in Patients with Primary Plasma Cell Leukemia
(PA-106) BCMA CAR T-cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001)
(PA-112) Navigating Myeloma: Behavioral and Emotional Outcomes from a Patient-Centered Navigation Resource
(PA-115) An Orthopaedic-guided Exercise Intervention for Newly Diagnosed Multiple Myeloma Patients Is Feasible, Safe and Improves Patient-reported Outcomes (GMMG-HD8-INDEX Trial)
(PA-118) Assessing the Correlation Between Canadian Multiple Myeloma Patients’ and Caregivers’ Perceived Quality of Life and Assessments of Validated Quality of Life Instruments
(PA-121) Patient-reported Quality of Life with Linvoseltamab in Triple-class Exposed Patients with Relapsed/refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial
(PA-124) Evaluating the Most Influential Factors in Decision-Making in Women and Men with Relapsed Multiple Myeloma
(PA-127) Survey-based Research into Patient-physician Communication and Treatment Decision-making Preferences in Newly Diagnosed Multiple Myeloma
(PA-131) Gender Disparities in Sexual Health Communication Among Patients with Multiple Myeloma: a HealthTree Patient Based Survey Study
(PA-134) Factors Influencing the Outcome of Salvage Second Autologous Stem Cell Transplant in Relapsed Multiple Myeloma
(PA-135) Evaluating the Efficacy and Tolerability of PJP Prophylaxis with TMP-SMX in Autologous Stem Cell Transplants for Lymphoma or Myeloma: A Retrospective Cohort Study
(PA-138) Health-related Quality of Life in a "Real-world" Cohort of Chilean Patients with Multiple Myeloma
(PA-141) The Optimising Outcomes in Myeloma Patients with Frailty (OOMPF) Study
(PA-146) Abstract: The Role of Caregivers in Multiple Myeloma Care: A Social Work Perspective at the Ampath Multiple Myeloma Program (AMMP)
(PA-149) Daratumumab versus Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Quality of Life and Efficacy Results from a Randomized Investigator-initiated Trial
(PA-152) PRO-Guided Treatment Readiness for Daratumumab in Myeloma: Feasibility and Accuracy
(PA-155) Diagnostic Potential of Shear Wave Elastography for Liver Involvement in AL Amyloidosis
(PA-158) The HSCT-BIOME Study: Double-blinded, Randomized, Placebo-controlled Trial Using Orally-administered, Lyophilized Faecal Microbiota Transplantation to Prevent Hsct-associated Complications
(PA-161) Assessing the Clinical Implications and Prognostic Value of Light-chain N-glycosylation in 781 Multiple Myeloma Patients at Diagnosis
(PA-164) Serum Cholesterol Levels Demonstrate Dynamic Changes Following Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
(PA-167) Measurable Residual Disease (MRD) Dynamics Reveals a Therapeutic Vulnerability State for Early Immunotherapy Interception in Multiple Myeloma (MM)
(PA-168) Advancing Soluble BCMA Quantification in Immunotherapy: Analytical Validation of ELLA versus ELISA for Predicting Toxicity and Response
(PA-171) Subclonal and Clonal Progression of Previously Characterized Mutations and Variants of Unknown Significance (VUS) Across a Cohort of Plasma Cell Dyscrasia Patients
(PA-174) Patient Perceptions of MRD Negativity as a Treatment Outcome and Regulatory Endpoint in Multiple Myeloma
(PA-177) Circulating Plasma Cells as an Independent Prognostic Marker in Newly Diagnosed Multiple Myeloma: Clinical Correlation and Immunophenotypic Insights
(PA-180) Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next-Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis
(PA-181) The New IMS / IMWG Consensus Risk Definition Predicts Outcomes with Daratumumab-based Quadruplet Regimens for Multiple Myeloma
(PA-184) Stem Cell Autograft Minimal Residual Disease Negativity Predicts Improved Outcomes After Autologous Stem Cell Transplant for Multiple Myeloma
(PA-185) Towards the Identification of Novel Circulating Biomarkers Associated with Bone Disease in Multiple Myeloma
(PA-188) Light Chain Escape in Multiple Myeloma: A Not-so-unusual Phenomenon
(PA-191) Lymphocyte to Monocyte Ratio at Minimal Residual Disease Assessment Predicted Survival Time Among Myeloma Patients in Complete Response
(PA-194) Detectable Peripheral Blood Measurable Residual Disease (PBMRD) Is Strongly Associated with Early Progression in Newly Diagnosed Multiple Myeloma (NDMM)
(PA-197) Utilization and Preferences of MRD Testing for Patients with Multiple Myeloma: Insights from a Survey of 251 North American Hematologists And/or Oncologists
(PA-201) Delayed and Sustained Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
(PA-204) Daratumumab-based Quadruplet Therapy in Functional High-risk RRMM (fRRMM) Patients Promotes CD8 T Cell Activation and Expansion in the Immune Microenvironment
(PA-207) Single-cell RNA-seq Studies Underline the Influence at Baseline of the BM Immune Composition in Promoting Resistance to CAR-T Therapies in Multiple Myeloma
(PA-210) Single-Nucleus Profiling Reveals Aberrant Osteoclast Differentiation in MM
(PA-213) Single-Cell Transcriptomic Stratification of Multiple Myeloma Reveals Oxidative Stress-Driven Subtypes and Cytogenetic Correlates
(PA-216) The PBX1 Protein Is Substantially Overexpressed in Patients with Multiple Myeloma Exhibiting Chromosomal 1q Gain or Amplification, and It Is Associated with Unfavorable Prognosis
(PA-219) CD69+ Bone Marrow-Resident CD8+ T Cells Exhibit Functional Exhaustion and Impaired Anti-Tumor Activity in Multiple Myeloma
(PA-223) GPRC5D and BCMA Genotypes in Relation to Diagnosis, Prognosis and Lenalidomide-based Maintenance Therapy in Multiple Myeloma Patients
(PA-228) A Novel Hypoxia Gene Signature from the HOVON-65/GMMG-HD4 Phase 3 Study Prognostic of Survival and Associated with Immune Suppression in the Tumor Microenvironment
(PA-231) Elevated Levels of Circulating Tumor Cells (CTCs) in Newly-diagnosed Multiple Myeloma (NDMM) Patients Reflect a Highly Proliferative and Genomically Complex Profile
(PA-234) Integrating Microenvironment with Tumor Multi-Omic using Unsupervised Machine Learning to Model Heterogeneity Refines Multiple Myeloma Subtypes and Reveals Immune-Based Clusters with Prognostic Impact
(PA-237) Integrative Genomic and Transcriptomic Profiling Reveals Distinct Characteristics of Immunoglobulin D Multiple Myeloma
(PA-240) Integrative Genetic Profiling of Circulating Tumour DNA And Bone Marrow for Multiple Myeloma Prognostication
(PA-243) Role and Mechanism of Multiple Myeloma Cells in Regulating Macrophage Polarization and the Antitumor Effect via ENO1
(PA-246) LILRB4 Drives Myeloid Immunosuppressive Microenvironment in Multiple Myeloma and Facilitates the Inferior Outcome of Patients
(PA-251) A Single-Cell Coding and Noncoding Transcriptomic Atlas Reveals ncRNA-Driven Remodeling of the Bone Marrow Microenvironment in Multiple Myeloma
(PA-255) Multi-hit Cytogenetics Risk Events Associated with IFN-I Suppression across TME of NDMM Patients and Poor Outcomes
(PA-256) Next-Generation Molecular Techniques as an Alternative to Conventional FISH in Newly Diagnosed Multiple Myeloma: A Pilot Study
(PA-260) Independent and Complementary Value of RNA Expression Signatures in High-Risk Multiple Myeloma
(PA-263) Temporal and Spatial Determinants of CAR-T Cell Therapy Efficacy in Multiple Myeloma
(PA-266) Monosomy 13 and Deletion of 13q Predict Inferior Outcomes in Multiple Myeloma Patients Undergoing Upfront Autologous Transplant
(PA-270) Spatial Transcriptomics Profiling Reveals Resistance Mechanisms in Extramedullary Myeloma Plasmacytomas Following CAR T-cell Therapy
(PA-273) Insights into Ubiquitination-Associated Genes in Multiple Myeloma: A Multi-Omics Mendelian Randomization Study
(PA-276) Macrophages Promote Aberrant DNA Repair in Multiple Myeloma via the CXCL5/CXCR2 Axis
(PA-279) NEDD4-1-Mediated Ubiquitination of CCR7 Reprograms Macrophage Function and Enhances theraputic Sensitivity in Multiple Myeloma.
(PA-282) Pan-RAS Inhibitor RMC-6236 Suppresses Myeloma Growth and Shows Enhanced Efficacy with SWI/SNF Inhibition
(PA-285) Secondary Clones Identified by Mass Spectrometry in Baseline Samples Remain Stable or Disappear Early During Monitoring in Multiple Myeloma Patients
(PA-290) Optimal Treatment Strategy of Bisphosphonate Therapy in Multiple Myeloma: A Target Trial Emulation Study of Fracture Prevention versus Osteonecrosis of the Jaw Risk Using Nationwide Data
(PA-293) Anti-adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma
(PA-297) Functional Evaluation of RHEB as a Lineage-Selective Dependency in Multiple Myeloma Using Integrated CRISPR, Epigenetic, and Expression Analyses
(PA-300) Autophagy Disruption via PIKfyve Inhibition Strikingly Upregulates Cholesterol Metabolism in Multiple Myeloma
(PA-303) STAT3 Inhibitors Inducing DNA Damage in Multiple Myeloma Cells and Enhancing the Anti-tumor Effects of NK Cells
(PA-307) IBERDOMIDE (IBER) TREATMENT (Tx) ENHANCES MANUFACTURED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL EXPANSION AND FUNCTIONALITY AND IS IMMUNOSTIMULATORY IN PATIENTS POST-CAR T CELL THERAPY
(PA-308) Efficacy and Safety of Daratumumab-Based Schemes in Over80_Years Newly Diagnosed Multiple Myeloma(NDMM)
(PA-311) Targeting of BIRC3 Sensitises Multiple Myeloma Cells to Proteasome Inhibitors
(PA-314) Exploiting Silver Nanoparticle (AgNP) Induced Proteotoxicity for Multiple Myeloma Treatment
(PA-319) Preclinical Activity of Pharmacological Inhibitors Targeting KRAS and pan-RAS in Multiple Myeloma
(PA-323) LILRB4 Protects Multiple Myeloma Cells from Ferroptosis to Promote MM Progression
(PA-324) AKR1B1/NAT10 Mediate IL4I1 ac4C Modification to Regulate Tryptophan Metabolism and Promote Multiple Myeloma Proliferation
(PA-325) RNF5-DNAJA1 Axis Dictates Selinexor Sensitivity of Multiple Myeloma
(PA-331) Real World Outcomes in Cardiac AL Amyloidosis: A Decade of Experience at a Multidisciplinary Amyloidosis Center
(PA-334) Successful Liver Transplantation for Acute Liver Failure Caused by AL Amyloidosis
(PA-337) Real-World Outcomes of Primary and Secondary Plasma Cell Leukemia: A Single-Institution Retrospective Study
(PA-340) Modeling Trajectories to Organ Recovery in AL Amyloidosis Using an Ensemble Machine Learning Approach
(PA-343) Comparing Smouldering Myeloma High-risk and Evolving Phenotype Definitions in the Prospective, Nationwide Uk Cosmos Study
(PA-347) SECURE Study: Early Findings Suggest MGUS Diagnosis Does Not Increase Psychological Distress
(PA-350) Association Between Metabolic Syndrome and Increased MGUS Risk in a Large Korean Cohort
(PA-353) Analysis of Clinical Characteristics and Prognostic Factors in Patients with Primary Plasma Cell Leukemia
(PA-357) The Natural History of Smoldering Multiple Myeloma (SMM): Evolution of Incidence and Progression Risk from 2005 to 2022 in a Nationwide Danish Population-Based Cohort
(PA-358) A Dynamic Risk Stratification Model for Patients with Smoldering Multiple Myeloma Through Integration of the Evolving Patterns of Monoclonal Protein and Serum Free Light Chains
(PA-361) Early Venetoclax Salvage in Systemic Light Chain Amyloidosis; A Retrospective Case Series
(PA-364) Clinical Outcomes of Patients with MGUS and Diabetes/obesity on GLP-1 Receptor Agonists: A Real-world, Propensity-matched Study
(PA-368) Mesenchymal Stromal Cell Senescence Is Associated with Progression from MGUS to Multiple Myeloma
(PA-369) Prior Plasma Cell Dyscrasia Is Associated with Lower Odds of Severe Myeloma-defining Events at Diagnosis
(PA-372) Real-World Outcomes and Treatment Patterns in Al-amyloidosis (AL-A) in Austria: An Analysis from the Austrian Interdiscplinary Amyloidosis Registry (AIDA)
(PA-374) MGUS Prevalence from a Large-Scale Community Study from Rural India (IMAGe-002B Study)
(PA-376) Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Not Planned for Upfront Autologous Stem Cell Transplant: Patient Disposition and MRD Outcomes from a Prospective Clinical Trial
(PA-381) Severe Infections in Newly Diagnosed Multiple Mieloma Patients Treated Frontline with Bortezomib, Lenalidomide and Dexamethasone (VRD) in Four Reference Centers
(PA-385) Prognostic Value of 1p Deletion in Newly Diagnosed Multiple Myeloma Patients: A Nationwide Multicenter Cohort Study by the Korean Multiple Myeloma Working Party (KMM2306)
(PA-388) Predicting Multiple Myeloma Mortality Using Long Short-term Memory Networks (LSTM)
(PA-391) The Novel High-risk Multiple Myeloma IMS/IMWG Criteria Identify Previously Overlooked Newly-diagnosed Patients with Poor Prognosis: Validation and Real-world Application
(PA-394) Propensity Score–Matched Comparison of Daratumumab–Rd versus Daratumumab–VMP in Transplant-Ineligible Multiple Myeloma Patients with del(17p13): An Analysis of the MAIA and ALCYONE Trials
(PA-397) Effects of Two Bortezomib-Based Protocols (VCD and VRD) on Responses and Survival as Induction Treatment of Patients with Multiple Myeloma Eligible for Autologous Stem Cell Transplantation
(PA-401) Intensified Cyclophosphamide, Bortezomib, Dexamethasone (iCyBorD) for the treatment of newly diagnosed Multiple Myeloma with Acute Kidney Injury
(PA-406) Efficacy and Safety of Bortezomib, Pomalidomide and Dexamethasone (VPD) in Newly Diagnosed Multiple Myeloma: Single-arm, Phase-II Investigator Initiated Prospective Clinical Trial
(PA-410) Cytarabine Plus G-CSF as Second Attempt in Very Poor Mobilizer Myeloma Patients After Cyclophosphamide Plus G-CSF and Plerixafor: Efficacy of Peripheral Blood Stem Cell (PBSC) Collection
(PA-413) Impact of Cumulative and Relative Dose Intensity of Bortezomib, Lenalidomide, and Dexamethasone (VRD) on Depth and Duration of Response in Newly Diagnosed Multiple Myeloma (MM)
(PA-418) Mortality and Trends of Multiple Myeloma in Brazil: A 27-Year Analysis.
(PA-421) Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian Countries
(PA-424) Daratumumab(Dara) Lenalidomide(R) Maintenance Following Dara-Carfilzomib(K)R Dexamethasone with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Update of the Phase 2 Study IFM 2018-04
(PA-427) Optimizing the Alcyone Trial: Efficacy of Daratumumab and Bortezomib Maintenance in Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients Post DVMP Induction, 2 Year Analysis
(PA-430) Recent Trends in Real-World Frontline Treatment Patterns and Outcomes for Patients with Multiple Myeloma in the United States
(PA-433) Frontline Anti-CD38 Monoclonal Antibodies in Patients with High-Risk, Newly Diagnosed Multiple Myeloma: A Meta Analysis
(PA-435) Survival Impact of Anti-CD38-Based Quadruplet Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis and Reconstructed Individual Patient Data Meta-Analysis
(PA-437) Real-World Evaluation of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Induction Followed by Daratumumab and Lenalidomide (DR) Maintenance in Transplant-Eligible Multiple Myeloma
(PA-441) Early Treatment with Daratumumab in Patients with Multiple Myeloma and Kidney Impairment: A Real-world Analysis
(PA-444) Evaluation of Haematopoietic Second Primary Malignancies in Multiple Myeloma: A Single Centre Australian Experience
(PA-447) Outcomes of Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Following VRD or KRD Induction Therapy
(PA-448) Survival of Light-chain Multiple Myeloma at the National Cancer Institute of Peru
(PA-451) Evaluating Racial and Ethnic Disparities in Progression Assessment Patterns in Routine Clinical Practice Among Patients with Newly Diagnosed Multiple Myeloma
(PA-452) Interim Analysis of DARA VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT as First Line in China
(PA-455) Dara-VCd in Newly Diagnosed Multiple Myeloma with Severe Renal Impairment: A Prospective Multicenter Single-Arm Study
(PA-458) Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on the Treatment of Multiple Myeloma: A Single-center Clinical Analysis on PFS
(PA-461) Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with High-risk Cytogenetics Abnormalities: A Single-arm, Multi-center, Observational Clinical Study
(PA-464) APOBEC3B-Driven Metabolic Adaptation Contributes to Bortezomib Resistance in Multiple Myeloma
(PA-467) Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma After Bortezomib and Lenalidomide: A Real-World Study
(PA-470) Analysis of Infectious Risk in the Multiple Myeloma Patients Treated with Bispecific Antibodies. Real World experience
(PA-475) DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy
(PA-480) BASECAMMP: An OBservational Retrospective Analysis of Treatment PatternS and Effectiveness of Standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor
(PA-483) Understanding Different Treatment (Tx) Goals and Experiences According to Characteristics in Relapsed/refractory Multiple Myeloma (RRMM)
(PA-486) RESCUE-LATAM Study: Real-world Evaluation of Salvage Combinations for Unmet needs in Expose and refractory multiple myeloma in LATAM Settings
(PA-491) Mezigdomide (MEZI) in Novel Combinations Effectively Reactivates Immune System in Patients with Relapsed/refractory Multiple Myeloma (RRMM) Including Those After T-cell–redirecting Therapies (TCRT)
(PA-495) Outcomes After Second Autologous Hematopoietic Cell Transplant in Patients with Relapsed Multiple Myeloma in Latin America
(PA-498) DARMMA – Real Life Experience of the Use of Daratumumab in Multiple Myeloma in Portugal
(PA-501) Characteristics and Outcomes of Multiple Myeloma Patients with Post-transplant Relapse: A Latin American Real-world Cohort Study
(PA-504) Patterns of Use, Outcomes and Tolerance to Daratumumab in Multiple Myeloma: A Single-centre Retrospective Study
(PA-508) Infection Rate Profile of Etentamig Monotherapy in Patients with Relapsed/refractory Multiple Myeloma
(PA-511) Exploration of Efficacy for Frailty-adjusted Dose-reduced Pcd Regimen in Relapsed/refractory Multiple Myeloma
(PA-514) Real-world Treatment Patterns, Effectiveness, and Safety of Daratumumab-based Regimens in Chinese Patients with Multiple Myeloma: Final Analysis of the MMY4032 Study
(PA-516) A Multi-omics Approach to Understanding Extramedullary Multiple Myeloma
(PA-519) Daratumumab-based Salvage Treatment for Multiple Myeloma: Experience from a Peruvian Institution
(PA-529) Risk of Infections After Bispecific Antibodies Targeting Anti-B-cell Maturation Antigen (BCMA) in Multiple Myeloma- intravenous Immunoglobulin (IVIG) Significantly Lowers the Risk of Infection
(PA-530) Second Primary Tumor in Patients with Multiple Myeloma in Brazil: A Population-Based Study
